Yduqs and Afya have announced a business combination through a merger, aiming to create a stronger combined entity. The companies shared forward-looking statements about their future growth prospects and combined financial results based on their second quarter 2026 metrics. The merger is expected to enhance operational and financial performance, although future outcomes depend on various external factors including market conditions and macroeconomic variables. Investors can access the full presentation and replay on Yduqs' website for more details.
Afya Limited merger news provides context for Health-sector stocks on Pluang. For readers following Health-sector stocks, here is Pluang's market snapshot as of Sep 25, 2026 02:11 WIB: 51 of 100 priced Health-sector US stocks rose while 48 fell. Notable movers include ACAD at USD 22.41 with a -11.88% change and 93% buy orders, FLNA at USD 0.79 with -11.55% change and 62% sell orders, and CRL at USD 297.79 with +7.38% change and balanced buy/sell activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
